Delta样配体4（Dll4）可预测透明细胞肾细胞癌的预后，且抗Dll4可在体内抑制肿瘤生长。
Delta-like ligand 4 (Dll4) predicts the prognosis of clear cell renal cell carcinoma, and anti-Dll4 suppresses tumor growth in vivo.
作者信息
Hu Guang-Hui, Liu Huan, Lai Peng, Guo Zhui-Feng, Xu Liang, Yao Xu-Dong, Zheng Jun-Hua, Liu Min, Xu Yun-Fei
机构信息
Department of Urology, Shanghai Tenth People's Hospital, Tongji University Shanghai, China.
出版信息
Int J Clin Exp Pathol. 2014 Apr 15;7(5):2143-52. eCollection 2014.
Abstract
The Delta-like ligand 4 (Dll4) and Notch signaling pathway plays a key role in embryonic vascular development and tumor growth. In this study, we measured the expression of Dll4 in clear cell renal cell carcinoma (ccRCC) and explored the correlation between Dll4 and ccRCC. We used sh-Dll4 treatment in a nude mouse model to observe the effect that inhibition of the Dll4/Notch pathway had on angiogenesis and vasculogenesis. We found up-regulation of Dll4 to be closely correlated with distant metastasis and worse overall survival. Cox regression analysis showed that Dll4 might be a prognostic marker of ccRCC. Blockade of Dll4/Notch signaling inhibited tumor growth in the mouse model via anti-angiogenesis and anti-vasculogenesis effects. We concluded that Dll4 might be a novel therapeutic target for the treatment of ccRCC.
摘要
Delta样配体4（Dll4）与Notch信号通路在胚胎血管发育和肿瘤生长中起关键作用。在本研究中，我们检测了Dll4在透明细胞肾细胞癌（ccRCC）中的表达，并探讨了Dll4与ccRCC之间的相关性。我们在裸鼠模型中使用sh-Dll4处理，以观察抑制Dll4/Notch通路对血管生成和血管发生的影响。我们发现Dll4的上调与远处转移及较差的总生存率密切相关。Cox回归分析表明，Dll4可能是ccRCC的一个预后标志物。在小鼠模型中，阻断Dll4/Notch信号通过抗血管生成和抗血管发生作用抑制肿瘤生长。我们得出结论，Dll4可能是治疗ccRCC的一个新的治疗靶点。
相似文献
1
Delta-like ligand 4 (Dll4) predicts the prognosis of clear cell renal cell carcinoma, and anti-Dll4 suppresses tumor growth in vivo.Delta样配体4（Dll4）可预测透明细胞肾细胞癌的预后，且抗Dll4可在体内抑制肿瘤生长。
Int J Clin Exp Pathol. 2014 Apr 15;7(5):2143-52. eCollection 2014.
2
Down-Regulated miR-30a in Clear Cell Renal Cell Carcinoma Correlated with Tumor Hematogenous Metastasis by Targeting Angiogenesis-Specific DLL4.透明细胞肾细胞癌中miR-30a表达下调通过靶向血管生成特异性DLL4与肿瘤血行转移相关。
PLoS One. 2013 Jun 27;8(6):e67294. doi: 10.1371/journal.pone.0067294. Print 2013.
3
Endothelial Delta-like 4 (DLL4) promotes renal cell carcinoma hematogenous metastasis.内皮细胞Delta样蛋白4（DLL4）促进肾细胞癌血行转移。
Oncotarget. 2014 May 30;5(10):3066-75. doi: 10.18632/oncotarget.1827.
4
Dicer suppresses MMP-2-mediated invasion and VEGFA-induced angiogenesis and serves as a promising prognostic biomarker in human clear cell renal cell carcinoma.Dicer抑制MMP - 2介导的侵袭和VEGFA诱导的血管生成，并作为人类透明细胞肾细胞癌中有前景的预后生物标志物。
Oncotarget. 2016 Dec 20;7(51):84299-84313. doi: 10.18632/oncotarget.12520.
5
Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.Dll4阻断增强了VEGF抑制在肾细胞癌患者来源异种移植模型中的抗肿瘤作用。
PLoS One. 2014 Nov 13;9(11):e112371. doi: 10.1371/journal.pone.0112371. eCollection 2014.
6
VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.VHL 突变介导的 SALL4 过表达通过 Akt/GSK-3β 信号通路促进肾透明细胞癌的发生和血管生成。
J Exp Clin Cancer Res. 2020 Jun 8;39(1):104. doi: 10.1186/s13046-020-01609-8.
7
Hsa_circ_0085576 promotes clear cell renal cell carcinoma tumorigenesis and metastasis through the miR-498/YAP1 axis.Hsa_circ_0085576 通过 miR-498/YAP1 轴促进肾透明细胞癌的发生和转移。
Aging (Albany NY). 2020 Jun 15;12(12):11530-11549. doi: 10.18632/aging.103300.
8
Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.DLL4/VEGF 双特异性治疗性抗体与伊立替康联合应用在胃癌中的协同抗肿瘤活性。
BMB Rep. 2020 Nov;53(10):533-538. doi: 10.5483/BMBRep.2020.53.10.103.
9
Combination DLL4 with Jagged1-siRNA can enhance inhibition of the proliferation and invasiveness activity of human gastric carcinoma by Notch1/VEGF pathway.将DLL4与Jagged1小干扰RNA联合使用可通过Notch1/VEGF途径增强对人胃癌增殖和侵袭活性的抑制作用。
Hepatogastroenterology. 2012 May;59(115):924-9. doi: 10.5754/hge11484.
10
The Vascular Notch Ligands Delta-Like Ligand 4 (DLL4) and Jagged1 (JAG1) Have Opposing Correlations with Microvascularization but a Uniform Prognostic Effect in Primary Glioblastoma: A Preliminary Study.血管切迹配体Delta样配体4（DLL4）和Jagged1（JAG1）与微血管形成呈相反的相关性，但在原发性胶质母细胞瘤中具有一致的预后影响：一项初步研究。
World Neurosurg. 2016 Apr;88:447-458. doi: 10.1016/j.wneu.2015.10.058. Epub 2015 Nov 4.
引用本文的文献
1
The Prediction of DLL4 as a Prognostic Biomarker in Patients with Gastric Cancer Using Anti-DLL4 Nanobody.抗 DLL4 纳米抗体预测胃癌患者 DLL4 作为预后生物标志物的研究
J Gastrointest Cancer. 2024 Sep;55(3):1380-1387. doi: 10.1007/s12029-024-01093-9. Epub 2024 Jul 24.
2
Prognostic Signatures and Therapeutic Value Based on the Notch Pathway in Renal Clear Cell Carcinoma.基于 Notch 通路的肾透明细胞癌预后标志物及治疗价值。
Oxid Med Cell Longev. 2022 Jan 20;2022:1669664. doi: 10.1155/2022/1669664. eCollection 2022.
3
Identification of ACTA2 as a Key Contributor to Venous Malformation.鉴定ACTA2是静脉畸形的关键促成因素。
Front Cell Dev Biol. 2021 Nov 8;9:755409. doi: 10.3389/fcell.2021.755409. eCollection 2021.
4
Correlation of serum delta-like ligand-4 level with the severity of diabetic retinopathy.血清 delta-like 配体 4 水平与糖尿病视网膜病变严重程度的相关性。
BMC Endocr Disord. 2021 Aug 6;21(1):157. doi: 10.1186/s12902-021-00814-6.
5
Notch Signaling Pathway in Cancer-Review with Bioinformatic Analysis.癌症中的Notch信号通路——基于生物信息学分析的综述
Cancers (Basel). 2021 Feb 12;13(4):768. doi: 10.3390/cancers13040768.
6
The Role of DLLs in Cancer: A Novel Therapeutic Target.DLLs在癌症中的作用：一种新型治疗靶点。
Onco Targets Ther. 2020 May 7;13:3881-3901. doi: 10.2147/OTT.S244860. eCollection 2020.
7
DLL4 as a predictor of pelvic lymph node metastasis and a novel prognostic biomarker in patients with early-stage cervical cancer.DLL4作为早期宫颈癌患者盆腔淋巴结转移的预测指标及一种新型预后生物标志物。
Tumour Biol. 2016 Apr;37(4):5063-74. doi: 10.1007/s13277-015-4312-3. Epub 2015 Nov 6.
8
Incomplete Dll4/Notch signaling inhibition promotes functional angiogenesis supporting the growth of skin papillomas.不完全抑制Dll4/Notch信号通路可促进功能性血管生成，支持皮肤乳头瘤生长。
BMC Cancer. 2015 Aug 28;15:608. doi: 10.1186/s12885-015-1605-2.
本文引用的文献
1
Blood flow suppresses vascular Notch signalling via dll4 and is required for angiogenesis in response to hypoxic signalling.血流通过 DLL4 抑制血管 Notch 信号转导，是血管生成对低氧信号反应所必需的。
Cardiovasc Res. 2013 Nov 1;100(2):252-61. doi: 10.1093/cvr/cvt170. Epub 2013 Jul 30.
2
Role of Notch signaling pathway in gastric cancer pathogenesis.Notch信号通路在胃癌发病机制中的作用。
Contemp Oncol (Pozn). 2013;17(1):1-5. doi: 10.5114/wo.2013.33765. Epub 2013 Mar 15.
3
Elevated DLL4 expression is correlated with VEGF and predicts poor prognosis of nasopharyngeal carcinoma.DLL4 表达升高与 VEGF 相关，并预示鼻咽癌预后不良。
Med Oncol. 2013 Mar;30(1):390. doi: 10.1007/s12032-012-0390-x. Epub 2012 Dec 30.
4
Delta like ligand 4 induces impaired chemo-drug delivery and enhanced chemoresistance in pancreatic cancer.Delta 样配体 4 诱导胰腺癌中化疗药物递送受损和化疗耐药增强。
Cancer Lett. 2013 Mar 1;330(1):11-21. doi: 10.1016/j.canlet.2012.11.015. Epub 2012 Nov 27.
5
Dll4-Fc, an inhibitor of Dll4-notch signaling, suppresses liver metastasis of small cell lung cancer cells through the downregulation of the NF-κB activity.Dll4-Fc，一种 Dll4-notch 信号通路的抑制剂，通过下调 NF-κB 活性抑制小细胞肺癌细胞的肝转移。
Mol Cancer Ther. 2012 Dec;11(12):2578-87. doi: 10.1158/1535-7163.MCT-12-0640. Epub 2012 Sep 18.
6
Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells.抗 DLL4 在胰腺癌中具有广谱活性，依赖于在肿瘤和血管细胞中靶向 DLL4-Notch 信号通路。
Clin Cancer Res. 2012 Oct 1;18(19):5374-86. doi: 10.1158/1078-0432.CCR-12-0736. Epub 2012 Sep 5.
7
The Notch signalling system: recent insights into the complexity of a conserved pathway.Notch 信号通路系统：对保守通路复杂性的最新见解。
Nat Rev Genet. 2012 Sep;13(9):654-66. doi: 10.1038/nrg3272. Epub 2012 Aug 7.
8
MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.MEDI0639：一种新型针对 Dll4 的治疗性抗体，可调节体内内皮细胞功能和血管生成。
Mol Cancer Ther. 2012 Aug;11(8):1650-60. doi: 10.1158/1535-7163.MCT-11-1027. Epub 2012 Jun 7.
9
Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI.比较血管内皮生长因子（VEGF）酪氨酸激酶抑制剂（TKI）和哺乳动物雷帕霉素靶蛋白（mTOR）抑制剂作为一线 VEGF TKI 治疗失败后转移性肾细胞癌患者二线治疗的疗效。
Med Oncol. 2012 Dec;29(5):3291-7. doi: 10.1007/s12032-012-0227-7. Epub 2012 Mar 30.
10
Delta-like ligand 4-notch blockade and tumor radiation response.Delta 样配体 4-Notch 阻断与肿瘤放射反应。
J Natl Cancer Inst. 2011 Dec 7;103(23):1778-98. doi: 10.1093/jnci/djr419. Epub 2011 Oct 18.
Zotero 插件